Credit Suisse Maintains Outperform on Ulta Beauty, Raises Price Target to $485
Credit Suisse analyst Michael Binetti maintains Ulta Beauty (NASDAQ:ULTA) with a Outperform and raises the price target from $475 to $485.
DA Davidson Maintains Buy on Ulta Beauty, Raises Price Target to $490
DA Davidson analyst Michael Baker maintains Ulta Beauty (NASDAQ:ULTA) with a Buy and raises the price target from $465 to $490.
Citigroup Maintains Neutral on Ulta Beauty, Raises Price Target to $425
Citigroup analyst Kelly Crago maintains Ulta Beauty (NASDAQ:ULTA) with a Neutral and raises the price target from $393 to $425.
70 Biggest Movers From Friday
Gainers
Avadel Pharmaceuticals plc (NASDAQ: AVDL) shares climbed 133.6% to close at $2.50 on Friday. Avadel Pharmaceuticals shares dipped 68% on Thursday after announcing new FDA request for experimental narcolepsy drug.
41 Stocks Moving In Friday’s Mid-Day Session
Gainers
Avadel Pharmaceuticals plc (NASDAQ: AVDL) shares rose 60.2% to $1.7136. Avadel Pharmaceuticals shares dipped 68% on Thursday after announcing new FDA request for experimental narcolepsy drug.
Where Ulta Beauty Stands With Analysts
Analysts have provided the following ratings for Ulta Beauty (NASDAQ:ULTA) within the last quarter:
Top 15 Trending Stocks On WallStreetBets As Of Tuesday, May 24, 2022 (Via Swaggy Stocks)
Data from https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment
GameStop (GME)
Tesla (TSLA)
NVIDIA (NVDA)
AMC Entertainment (AMC)
Apple (AAPL)
Amazon.com (AMZN)
Advanced Micro Devices
Oppenheimer Maintains Outperform on Ulta Beauty, Raises Price Target to $485
Oppenheimer analyst Rupesh Parikh maintains Ulta Beauty (NASDAQ:ULTA) with a Outperform and raises the price target from $470 to $485.